Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Immunology/Tumor Immunobiology 5: Tumors and the Immune System: Immunotherapy and Immunomodulation II

Suppression of CD3-zeta and JAK3 by a circulating factor from ovarian cancer patients.

Douglas D. Taylor and Cicek Gercel-Taylor
Douglas D. Taylor
University of Louisville School of Medicine, Louisville, KY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cicek Gercel-Taylor
University of Louisville School of Medicine, Louisville, KY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2004
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 45, 2004

Abstract

2178

Objective: While the loss of CD3-ζ is a common observation in invasive ovarian cancer, the mechanisms responsible for this decreased expression remains unknown. We have identified a circulating 14kD ζ inhibitor that can mimic in vitro many of the cellular events associated with suppressed cellular immunity, corresponding to immunotrophism. Previous investigations have separately demonstrated links between CD3-ζ and JAK3 expressions, between induction of T-cell apoptosis and CD3-ζ expression, and between JAK3 expression and induction of T-cell apoptosis. Our hypothesis is that this ζ inhibitor represents a central regulatory site, modulating expression of CD3-ζ and JAK3. Methods of Study: Blood samples were obtained from normal female controls (n=15) and women with ovarian cancer (n=30). ζ inhibitory factor was partially purified using Sepharcyl S200, followed by RP-HPLC. Jurkat cells (106 cells/ml) were incubated in medium containing 10ng/ml of the serum-derived inhibitor. After 24, 48 and 96 hours, aliquots of cells were removed, the cells centrifuged, and the pellet washed and lyzed. The cellular expression of CD3-ζ, JAK3, bcl-2 and bax were evaluated by western immunoblotting. To examine activated JAK3 expression, Jurkat cells (2×106) were incubated with 10ng/ml ζ inhibitor alone or with 2μM phorbol 12,13 butyrate, 0.64μM ionomycin for 24 hours at 37°C. For apoptosis studies, Jurkat cells (5×106 cells) were incubated for 24 hours with media alone, media containing 10% control normal serum, media containing 10ng/ml ζ inhibitor (isolated from 3 ovarian cancer patients), anti-Fas antibody, or cisplatin (as positive controls) using a Cell Death ELISA. Results: The ζ inhibitor from ovarian cancer patients (at 10ng/ml) inhibited the expression of CD3-ζ (83.7% reduction, p <0.001), while sera from normal volunteers failed to significantly affect ζ expression. When the effect of the serum-derived inhibitor was assessed on cellular expression of JAK3, the presence of ζ inhibitor suppressed both the constitutive (decreased 34%, p<0.001) and induced (76%, p<0.001) expression of JAK3 in T-cells. The ζ inhibitor preparations appeared to induce a significant increase in the level of apoptosis observed within Jurkat cells (2.17 fold increase, p<0.0001). This finding paralleled our finding of increased DNA fragmentation in ζ inhibitor-treated Jurkat cells. Under the same treatment conditions, the pro-apoptotic protein (bax) was elevated 1.46 fold (p=0.001) by exposure to the ζ inhibitor, while the anti-apoptotic protein (bcl-2) was slightly decreased (1.24 fold, p=0.018). Conclusions: The presence of serum-derived ζ inhibitor correlates with the ability to inhibit both CD3-ζ and JAK3. The exposure of T cells to the ζ inihibitor induces apoptosis, apparently via the combination of enhanced expression of bax and supressed bcl-2, which are regulated by JAK3 levels.

  • American Association for Cancer Research
Previous
Back to top
April 2004
Volume 64, Issue 7 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Suppression of CD3-zeta and JAK3 by a circulating factor from ovarian cancer patients.
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Suppression of CD3-zeta and JAK3 by a circulating factor from ovarian cancer patients.
Douglas D. Taylor and Cicek Gercel-Taylor
Cancer Res April 1 2004 (64) (7 Supplement) 501-502;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Suppression of CD3-zeta and JAK3 by a circulating factor from ovarian cancer patients.
Douglas D. Taylor and Cicek Gercel-Taylor
Cancer Res April 1 2004 (64) (7 Supplement) 501-502;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Recombinant Listeria monocytogenes-based immunotherapy targeting the receptor tyrosine kinase EphA2.
  • Adoptive immunotherapy with polyclonal tumor-reactive CD8 T cells hyperexpanded to greater than 108-fold.
  • Enhancement of antitumor immunity following depletion of CD4+CD25+ regulatory T cells.
Show more Immunology/Tumor Immunobiology 5: Tumors and the Immune System: Immunotherapy and Immunomodulation II
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement